S&P 500   3,299.31 (+1.62%)
DOW   27,182.74 (+1.37%)
QQQ   271.80 (+2.42%)
AAPL   112.05 (+3.54%)
MSFT   208.59 (+2.66%)
FB   255.03 (+2.20%)
GOOGL   1,442.73 (+1.40%)
AMZN   3,093.65 (+2.45%)
TSLA   404.76 (+4.38%)
NVDA   512.61 (+3.78%)
BABA   270.87 (+0.42%)
CGC   14.23 (-0.28%)
GE   6.13 (+1.16%)
MU   49.02 (-0.91%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.53 (-1.95%)
ACB   5.04 (-3.08%)
GILD   62.39 (+0.22%)
NFLX   483.73 (+2.25%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.68 (+5.91%)
S&P 500   3,299.31 (+1.62%)
DOW   27,182.74 (+1.37%)
QQQ   271.80 (+2.42%)
AAPL   112.05 (+3.54%)
MSFT   208.59 (+2.66%)
FB   255.03 (+2.20%)
GOOGL   1,442.73 (+1.40%)
AMZN   3,093.65 (+2.45%)
TSLA   404.76 (+4.38%)
NVDA   512.61 (+3.78%)
BABA   270.87 (+0.42%)
CGC   14.23 (-0.28%)
GE   6.13 (+1.16%)
MU   49.02 (-0.91%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.53 (-1.95%)
ACB   5.04 (-3.08%)
GILD   62.39 (+0.22%)
NFLX   483.73 (+2.25%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.68 (+5.91%)
S&P 500   3,299.31 (+1.62%)
DOW   27,182.74 (+1.37%)
QQQ   271.80 (+2.42%)
AAPL   112.05 (+3.54%)
MSFT   208.59 (+2.66%)
FB   255.03 (+2.20%)
GOOGL   1,442.73 (+1.40%)
AMZN   3,093.65 (+2.45%)
TSLA   404.76 (+4.38%)
NVDA   512.61 (+3.78%)
BABA   270.87 (+0.42%)
CGC   14.23 (-0.28%)
GE   6.13 (+1.16%)
MU   49.02 (-0.91%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.53 (-1.95%)
ACB   5.04 (-3.08%)
GILD   62.39 (+0.22%)
NFLX   483.73 (+2.25%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.68 (+5.91%)
S&P 500   3,299.31 (+1.62%)
DOW   27,182.74 (+1.37%)
QQQ   271.80 (+2.42%)
AAPL   112.05 (+3.54%)
MSFT   208.59 (+2.66%)
FB   255.03 (+2.20%)
GOOGL   1,442.73 (+1.40%)
AMZN   3,093.65 (+2.45%)
TSLA   404.76 (+4.38%)
NVDA   512.61 (+3.78%)
BABA   270.87 (+0.42%)
CGC   14.23 (-0.28%)
GE   6.13 (+1.16%)
MU   49.02 (-0.91%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.53 (-1.95%)
ACB   5.04 (-3.08%)
GILD   62.39 (+0.22%)
NFLX   483.73 (+2.25%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.68 (+5.91%)
Log in
NASDAQ:DXCM

DexCom Stock Forecast, Price & News

$401.27
+19.24 (+5.04 %)
(As of 09/25/2020 03:21 PM ET)
Add
Compare
Today's Range
$376.80
Now: $401.27
$401.76
50-Day Range
$383.46
MA: $413.98
$451.79
52-Week Range
$145.23
Now: $401.27
$456.23
Volume11,860 shs
Average Volume1.28 million shs
Market Capitalization$38.42 billion
P/E Ratio183.23
Dividend YieldN/A
Beta0.81
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
DexCom logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.44 per share
Book Value$9.64 per share

Profitability

Net Income$101.10 million

Miscellaneous

Employees3,900
Market Cap$38.42 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$401.27
+19.24 (+5.04 %)
(As of 09/25/2020 03:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DexCom (NASDAQ:DXCM) Frequently Asked Questions

How has DexCom's stock been impacted by COVID-19?

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DXCM shares have increased by 59.0% and is now trading at $401.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DexCom?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom
.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for DexCom
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Tuesday, July, 28th. The medical device company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.48. The medical device company earned $451.80 million during the quarter, compared to analyst estimates of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The firm's revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.08 EPS.
View DexCom's earnings history
.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.85 billion, compared to the consensus revenue estimate of $1.8 billion.

What price target have analysts set for DXCM?

20 analysts have issued 1-year price objectives for DexCom's stock. Their forecasts range from $200.00 to $500.00. On average, they anticipate DexCom's share price to reach $403.89 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price.
View analysts' price targets for DexCom
.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), Trade Desk (TTD), Walt Disney (DIS), Shopify (SHOP) and Advanced Micro Devices (AMD).

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.73%), Mint Tower Capital Management B.V. (8.20%), Jennison Associates LLC (2.88%), Blair William & Co. IL (1.12%), GQG Partners LLC (0.63%) and Federated Hermes Inc. (0.61%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom
.

Which major investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Holocene Advisors LP, Columbus Circle Investors, Ardevora Asset Management LLP, Neuberger Berman Group LLC, Frontier Capital Management Co. LLC, Orbimed Advisors LLC, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom
.

Which major investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Vanguard Group Inc., Charles Schwab Investment Management Inc., Coatue Management LLC, GQG Partners LLC, Principal Financial Group Inc., Principal Financial Group Inc., and New York State Teachers Retirement System.
View insider buying and selling activity for DexCom
.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $401.27.

How big of a company is DexCom?

DexCom has a market capitalization of $38.42 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.